CAJ | 학술논문

抗肿瘤坏死因子-α(anti-TNF-α)是新型的能够有效治疗难治性炎症性肠病(IBD)的药物,但也有许多不良反应,需要小心监控治疗.其中英夫利昔单抗的应用最为广泛,本文对其治疗IBD的潜在风险进行综述,包括输液反应、恶性肿瘤、结核、感染、红斑狼疮等.
항종류배사인자-α(anti-TNF-α)시신형적능구유효치료난치성염증성장병(IBD)적약물,단야유허다불량반응,수요소심감공치료.기중영부리석단항적응용최위엄범,본문대기치료IBD적잠재풍험진행종술,포괄수액반응、악성종류、결핵、감염、홍반랑창등.
@@@@[Absract] Anti-TNF-αis a new and an effective treatment option for refractory IBD, but it has many the potential side effects that necessitate careful monitoring of therapy. Monoclonal antibody of infliximab is most widely used, and the potential risks of the treatment for IBD are summarized in this paper, including infusion reaction, maglignancy, tuberculosis, infection, lupus and so on.